Abstract | BACKGROUND: MATERIAL/METHODS: We conducted a comprehensive meta-analysis of studies to appraise the efficacy and safety of flurbiprofen axetil for controlling pain induced by propofol injection. The pooled risk ratio (RR) with corresponding 95% confidence intervals (CI) was calculated employing fixed- or random-effects models, depending upon the heterogeneity of the included trials. RESULTS: Compared with the placebo group, flurbiprofen axetil allows more patients to have no pain (RR 3.51, 95% CI 2.22-5.55, p=0.000), and decreases the cumulative number of patients with mild, moderate, and severe pain on injecting propofol (RR 0.70, 95% CI 0.58-0.86, p=0.000; RR 0.59, 95% CI 0.46-0.75, p=0.000; RR 0.25, 95% CI 0.16-0.38, p=0.000, respectively). In the stratified analysis by the doses, flurbiprofen axetil at a dose of over 50 mg was found to be effective in reducing propofol-induced pain on injection; however, there were no significant differences in relieving pain between treatment and placebo groups with flurbiprofen axetil at a dose of 25 mg. In terms of drug safety, there were no adverse effects (AEs) reported between flurbiprofen axetil-based regimens and placebo regimens. CONCLUSIONS:
|
Authors | Lieliang Zhang, Juan Zhu, Lei Xu, Xunlei Zhang, Hongyu Wang, Zhonghua Luo, Yamei Zhao, Yi Yu, Yong Zhang, Hongwei Shi, Hongguang Bao |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 20
Pg. 995-1002
(Jun 17 2014)
ISSN: 1643-3750 [Electronic] United States |
PMID | 24935068
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Flurbiprofen
- flurbiprofen axetil
- Propofol
|
Topics |
- Clinical Trials as Topic
- Flurbiprofen
(adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Pain
(drug therapy, etiology, prevention & control)
- Propofol
(administration & dosage, adverse effects)
- Publication Bias
- Risk Factors
- Treatment Outcome
|